Briefcases -- All Litigations -- ACTEMRA INVESTIGATION BY Mass Tort Nexus (tocilizumab) from Genentech (Roche) Re: Rheumetoid Arthritis Drug (FDA Approval October 2008)
ACTEMRA INVESTIGATION BY Mass Tort Nexus (tocilizumab) from Genentech (Roche) Re: Rheumetoid Arthritis Drug (FDA Approval October 2008)
Case Files
News
Easy Button
Committees

Categories

Sort by:
  1. ACTEMRA (tocilizumab): FDA and EU Analysis, Studies and Research 1 of 2 Re: Genentech (Roche) - Rheumatoid Arthritis FDA Drug Approval October 2008
  2. ACTEMRA (tocilizumab): FDA and EU Analysis, Studies and Research 2 of 2 Re: Genentech (Roche) - Rheumatoid Arthritis FDA Drug Approval October 2008
  3. ACTEMRA (tocilizumab) by Genentech (Roche) Re: Rheumatoid Arthritis FDA Drug Approval October 2008
    1. ACTEMRA (tocilizumab) Evidentiary Documents

Documents

Sort by:
  1. 2008-4371b1-01-FDA Meeting Summary 2008.pdf
  2. Australian Public Assessment Report for tocilizumab (rch) Proprietary Product Name: Actemra Sponsor: Roche Products Pty Ltd
  3. Ablynx: Study of Nanobodies by Flanders Institute Science Faculty - Pharmaceuticals and Biotechnologies (2013)
  4. Current Developments in U.S. Patent Law: Fordham IP Institute by Dimitrios T. Drivas April 24, 2014
  5. Actemra FDA Clinical Pharmacology Reviews.pdf
  6. Actemra FDA Microbiology Reviews.pdf
  7. Acterma FDA Label Change March 2017.pdf
  8. Acterma FDA Label Change May 2017.pdf
  9. Acterma FDA Label May 2013.pdf
  10. Acterma FDA Label October 2012.pdf
  11. Acterma FDA Supplemental Approval 2017.pdf
  12. Treatment options in patients with rheumatoid arthritis failing.pdf
  13. Ablynx: Study Part II of Nanobodies by Flanders Institute Science Faculty - Pharmaceuticals and Biotechnologies (2013)
  14. Comaprative Study Re: Abbott and Roche in Powerpoint by Mr Amin Rajani
  15. Coventry Health Care of Missouri Insurance Coverage Analysis March 25, 2014 in Powerpoint
  16. fig1_10.1002%2Fart.23940.pptx
  17. fig2_10.1002%2Fart.23940.pptx
  18. fig4_10.1002%2Fart.23940.pptx
  19. ROCHE: A Strategic Business Analysis in Powerpoint
  20. Rheumatoid Arthritis World Map Deaths Per Million Persons by World Health Organization 2012
  21. Stidham_IBD-Update-Talk-Final.pptx
  22. T1_Results_Slideset_3_4_15.pptx
  23. the-role-of-tocilizumab-monotherapy-in-the-management-of-rheumatoid-arthritis-a-review.pdf
  24. Tocilizumab and tofacitinib increase lipids in RA patients _ Rheumatology News.pdf
  25. Tocilizumab in rheumatoid arthritis A case study of safety evaluations.pdf
  26. tocilizumab__RoActemra__FINAL_July_2014_for_website.pdf
  27. Tocilizumab_2017_updatedDSedits_170220.pdf
  28. Tocilizumab Protocol FRI June 19, 2015
  29. Tocilizumabinterim_monograph_16June2010_formatted.pdf
  30. Actemra EU Med Agency Giant Cell.pdf
  31. Actemra FDA Chemistry Reviews.pdf
  32. Actemra FDA Approval Letter for Oct 2013 Label.pdf
  33. Actemra FDA Enviromental Reviews.pdf
  34. Actemra FDA General Reviews.pdf
  35. Actemra FDA Label Revised May 2017.pdf
  36. Actemra FDA Label Update Oct 2013.pdf
  37. Actemra FDA Other Reviews.pdf
  38. Actemra FDA Pharmcological Reviews.pdf
  39. Actemra FDA Prop Name Reviews.pdf
  40. Actemra FDA Risk Assessment Reviews.pdf
  41. Actemra FDA Statistical Reviews.pdf
  42. Actemra FDA Summary Review for Oct 2013 Label.pdf
  43. Actemra TGA Austrailia.pdf
  44. Acterma FDA Labeling-Medication Guide 2017.pdf
  45. Acterma FDA Label Change September 2013.pdf
  46. Acterma FDA Efficacy-Labeling Change With Clinical Data September 2016.pdf
  47. Acterma FDA Label April 2011 Supplement.pdf
  48. Acterma FDA Label April 2011.pdf
  49. Acterma FDA Label April 2013.pdf
  50. Acterma FDA Label August 2012.pdf
  51. Acterma FDA Label Jan 2010.pdf
  52. Acterma FDA Label Jan 2011 Supplement 2.pdf
  53. Acterma FDA Label Jan 2011 Supplement.pdf
  54. Acterma FDA Label January 2011.pdf
  55. Acterma FDA Label March 2017.pdf
  56. Acterma FDA Label October 2013.pdf
  57. Acterma FDA Label October 2016.pdf
  58. Acterma FDA REMS Changes August 2015.pdf
  59. Acterma Initial FDA Approval Letter January 8 2010.pdf
  60. Acterma Initial FDA Label 2010.pdf
  61. DHCP Letter Canada.pdf
  62. Tocilizumab raises cholesterol, but not cardiovascular events _ Rheumatology News.pdf
  63. Tocilizumab raises cholesterol, but not cardiovascular events _ Rheumatology News.pdf
  64. fig3_10.1002%2Fart.23940.pptx
  65. fig5_10.1002%2Fart.23940.pptx
  66. Rheumatoid_arthritis_world_map-Deaths_per_million_persons-WHO2012.svg.png
  67. ROCHE: A Strategic Business Analysis in Powerpoint
  68. Tocilizumab_2017_updatedDSedits_170220 (1).pdf
View All